Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Kearon and colleagues1 compared the use of fixed-dose, weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute venous thromboembolism (VTE). One of the key findings was the small risk of major bleeding at 10 days, although there was a non–statistically significant difference at 3 months (1.7% for the unfractionated heparin group vs 3.4% for the low-molecular-weight heparin group).
Bhala N, Shah A, King A, Molugu C. Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism. JAMA. 2007;297(3):261-263. doi:10.1001/jama.297.3.261-a